Recap: Theravance Biopharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
Theravance Biopharma (NASDAQ:TBPH) reported Q4 earnings with an EPS of $-0.17, missing estimates by -13.0% against an expected $-0.15. Revenue increased by $2.92 million from the previous year. Despite missing this quarter's earnings estimate, the company had previously beaten EPS estimates in Q3 2023, which led to a 5.0% share price increase the following day.
February 26, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theravance Biopharma reported a Q4 EPS of $-0.17, missing estimates by -13.0%, with a revenue increase of $2.92 million from the previous year. The company had previously seen a share price increase following a positive earnings surprise in Q3 2023.
Missing the earnings estimate could lead to a negative short-term impact on TBPH's stock price, as historical data shows its price is sensitive to earnings reports. The previous quarter's positive surprise led to a share price increase, indicating that investors may react negatively to this earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100